Sanofi (Euronext:SAN; NASDAQ:SNY) said FDA approved Cablivi caplacizumab-yhdp to treat acquired thrombotic thrombocytopenic purpura (aTTP), making it the first FDA-approved therapy for the rare blood clotting disorder. Sanofi will launch the drug late this quarter at a wholesale acquisition cost of $270,000 per aTTP episode.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,